Progressive multifocal leukoencephalopathy (PML) is a rare, typically fatal, demyelinating central nervous system infection caused by reactivation of the John Cunningham virus that generally occurs in immunosuppressed patients. With an…
The use of biologics such as anti–tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung…
Immune checkpoint inhibitors (ICIs) are increasingly studied and used as therapy for a growing number of malignancies. ICIs work by blocking inhibitory pathways of T-cell activation, leading to an immune…
Cancer is a common event in patients with rheumatic diseases. In some cases, the disease, its risk factors, or its treatment could play a role in favoring cancer. This article…
For as long as there have been immunizations, there have been barriers to them. Immunization rates in the United States are below target. Rheumatologists and rheumatology practitioners need to understand…
Patients being treated with biological therapies are at increased risk for serious infections, including opportunistic infections. Although more is known about opportunistic infection risk with older biologics, such as antitumor…
Patients with rheumatoid arthritis are highly vulnerable to infections because of abnormalities in their immune system, and because of immunosuppressive effects of their medications. Vaccinations in this population are complicated…
Michael H. Weisman, MD, Consulting Editor This issue, edited and crafted by Winthrop and Calabrese, is spectacular. No one could have done a better job. The data and commentary will…
Kevin L. Winthrop, MD, MPH, Editor Leonard H. Calabrese, DO, Editor
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA www.rheumatic.theclinics.com Consulting Editor MICHAEL H. WEISMAN February 2017 • Volume 43 • Number 1
